January 25th 2023
If approved on its March PDUFA date, rezafungin could be the first new Candida treatment option in over a decade.
January 16th 2023
Containing an Outbreak of Carbapenem-Resistant Acinetobacter baumannii in a COVID-19 Isolation Unit
October 20th 2022COVID-19 isolation wards should employ additional contact precautions and environmental cleaning alongside regular COVID-19 precautions, such as personal protective equipment, in order to prevent multidrug-resistant infections.
Read More
Novel Antibiotics for Resistant Pathogens: Results of ATTACK Trial for Sulbactam-Durlobactam
April 26th 2022Entasis Therapeutics gave 2 oral presentations at ECCMID today detailing results of their ATTACK trial, investigating the safety and efficacy of sulbactam-durlobactam (SUL-DUR) for multidrug-resistant pathogens.
Read More
Identifying High-Risk Recurrent Clostridioides Difficile Patients for Bezlotoxumab
April 18th 2022The greatest risk factors for recurrent Clostridioides difficile infection (CDI) were age of at least 65 years, severe primary CDI, and use of non-CDI antibiotics. Patients with these risk factors should be prioritized for bezlotoxumab therapy.
Read More
Ferring’s Microbiome Health Index Measures Gut Microbiota After Antibiotics
January 7th 2022Ferring’s Microbiome Health Index is a diagnostic tool that may help distinguish a healthy gut microbiome from post-antibiotic dysbiosis, and could potentially identify debilitating illnesses such as C difficile infection
Read More